Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT02452372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 6, 2015
Completion date
September 6, 2017
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute intermittent porphyria